Remove 2026 Remove Hospitals Remove Insurance Coverage and Processing
article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture

Pharmaceutical Technology

By incorporating a cell line from AvenCell into good manufacturing practice processes, ViroCell met the challenge of delivering a high-yield vector within the required timeframe. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Topic sponsors are not involved in the creation of editorial content.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DSCSA Compliance Has Arrived. Now What?

Pharmaceutical Commerce

Transition to NDC-12 codes will significantly impact the pharmaceutical supply chain, affecting manufacturing, distribution, and reimbursement processes. Increased regulatory engagement highlights the importance of updating SOPs to ensure compliance and effective documentation of processes. 27, 2026, respectively.

article thumbnail

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Pharmaceutical Technology

Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. A decision by the FDA is expected in H1 2026. MAXSHOT.PL via Shutterstock.

article thumbnail

JCR Pharma and Alexion partner on JUST-AAV gene therapy platform

Pharmaceutical Technology

The financial impact of this agreement on JCR’s consolidated results for the fiscal year ending 31 March 2026 has already been included in the current earnings forecast. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. JUST-AAV is a proprietary platform technology that employs modified AAV vectors.

article thumbnail

Sarepta halts Elevidys shipments following FDA pressure

Pharmaceutical Technology

It is important for the patients we serve that Sarepta maintains a productive and positive working relationship with FDA, and it became obvious that maintaining that productive working relationship required this temporary suspension while we address any questions that FDA may have and complete the Elevidys label supplement process.”

article thumbnail

Sarepta allowed to continue US Elevidys shipments

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Despite being a different drug, it is built on the same viral vector as Elevidys, a recombinant adeno-associated viral vector (AAV) called AAVrh74. Editorial content is independently produced and follows the highest standards of journalistic integrity.